Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05127486 · ClinicalTrials.gov registry record · Phase 4
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
A Phase 4 study of Migraine and Episodic Migraine, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 580
- Enrollment target
- 20
- Study locations
NCT05127486 is a Phase 4 study of Migraine and Episodic Migraine that has completed, run by Eli Lilly and Company. The registered enrollment target is 580 participants, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (64% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT05127486, a Phase 4 study of Migraine and Episodic Migraine, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 580 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the prevention of migraine in participants with episodic migraine. The study duration will be approximately 6 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rimegepant
- DRUG Galcanezumab
Study Locations (20)
California
- Velocity Clinical Research, Banning - Banning
- Velocity Clinical Research, Chula Vista - Chula Vista
- Wr- Pri, Llc - Encino
- Velocity Clinical Research, San Diego - La Mesa
- California Medical Clinic for Headache and The Los Angeles Headache Center (Research Facility) - Los Angeles
- Pharmacology Research Institute - Newport Beach
- Velocity Clinical Research, North Hollywood - North Hollywood
- Anderson Clinical Research - Redlands
- Center for Clinical Trials of Sacramento - Sacramento
- Velocity Clinical Research, Huntington Park - Santa Ana
- Encompass Clinical Research - Spring Valley
Florida
- Innovative Research of West Florida - Clearwater
- AMR Miami - Coral Gables
- Accel Research Sites- Clinical Research Unit - DeLand
- Velocity Clinical Research, Hallandale Beach - Hallandale
- Accel Research Sites-LKD CRU - Lakeland
Arizona
- Gilbert Neurology - Gilbert
- Foothills Research Center / CCT Research - Phoenix
- Alliance for Multispecialty Research, LLC Tempe - Tempe
Connecticut
- CMR of Greater New Haven, LLC - Hamden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 580 participants |
| Start Date | 2021-12-06 |
| Est. Completion | 2023-05-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05127486
The ClinicalTrials.gov registry entry for NCT05127486 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 580 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (64% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Migraine appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05127486 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05127486 about?
NCT05127486 is a clinical study titled "A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine". The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the prevention of migraine in participants with episodic migraine. The study duration will be approximately 6 months.
What is the current status of trial NCT05127486?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 580 participants. The study started on 2021-12-06. Estimated completion is 2023-05-23.
What conditions does trial NCT05127486 study?
This clinical trial studies the following conditions: Migraine, Episodic Migraine.
What interventions are being tested in trial NCT05127486?
The interventions under investigation include: Placebo (DRUG), Rimegepant (DRUG), Galcanezumab (DRUG).
Who is sponsoring clinical trial NCT05127486?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05127486 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
RECRUITING · Phase 4
-
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
RECRUITING · Phase 4
-
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
RECRUITING · Phase 4
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
RECRUITING · Phase 4
-
Nerivio Efficacy Under High-Frequency Use
ACTIVE NOT RECRUITING · Phase 4
-
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.